What is the standard management for localized, superficial bladder cancer?

What is the standard management for localized, superficial bladder cancer?

• A. Radical cystectomy with chemotherapy
• B. Transurethral resection with electrocautery and follow-up every 3 months
• C. Radiation therapy alone
• D. Observation

Answer: (B)

The main idea is that superficial bladder cancers are treated by removing the tumor and then watching closely for recurrence. The best approach is transurethral resection of the bladder tumor with electrocautery to completely remove the visible lesion and obtain tissue for pathology. This not only treats the existing tumor but also provides accurate staging and helps guide further treatment. Because these tumors tend to come back even after successful resection, rigorous follow-up is essential. The typical plan is cystoscopic surveillance every few months—commonly every 3 months in the early years—to detect and resect any recurrent tumors promptly, reducing the chance of progression. Other strategies, like radical cystectomy, radiation alone, or simply observing, aren’t appropriate for localized, superficial disease as first-line management, because they either over-treat, under-treat, or miss early recurrences.

The main idea is that superficial bladder cancers are treated by removing the tumor and then watching closely for recurrence. The best approach is transurethral resection of the bladder tumor with electrocautery to completely remove the visible lesion and obtain tissue for pathology. This not only treats the existing tumor but also provides accurate staging and helps guide further treatment.

Because these tumors tend to come back even after successful resection, rigorous follow-up is essential. The typical plan is cystoscopic surveillance every few months—commonly every 3 months in the early years—to detect and resect any recurrent tumors promptly, reducing the chance of progression.

Other strategies, like radical cystectomy, radiation alone, or simply observing, aren’t appropriate for localized, superficial disease as first-line management, because they either over-treat, under-treat, or miss early recurrences.